141
Participants
Start Date
May 13, 2025
Primary Completion Date
May 31, 2029
Study Completion Date
May 31, 2029
Psilocybin
The psilocybin used in this study is synthesized under Good Manufacturing Practice (GMP) guidelines and is provided in a capsule containing 25 mg of synthetic psilocybin.
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)
Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear.
Sham taVNS
Participants will be provided with a taVNS device and trained on its use. The device delivers gentle stimulation to the left ear. In the sham condition, the device will simulate the sensations of active taVNS without delivering therapeutic stimulation.
RECRUITING
Vail Health Behavioral Health, Edwards
Usona Institute
OTHER
Tiny Blue Dot Foundation
OTHER
Steadman Philippon Research Institute
OTHER
Emory University
OTHER
Charles Raison
OTHER